Dimebon (latrepirdine) / BioXcel, BIGESPAS - LARVOL DELTA

Latrepirdine (Dimebon), a potent 5-HT7 receptor antagonist, modulates stress-mediated behaviors in rodents. (PubMed, Front Pharmacol) - "These effects may account for the neuropsychiatric effects detected in the clinic. Latrepirdine has properties that suggest it would be a useful drug for the chronic treatment of stress-induced and anxiety-related symptoms."

Journal • Preclinical • Mood Disorders • Psychiatry • Sleep Disorder

Efficacy and safety of DMB-I (latrepirdine) therapy in mild to moderate dementia in Alzheimer's disease: results of a multicenter, double-blind, randomized, placebo-controlled, clinical trial in three parallel groups. (PubMed, Sci Rep) - P2 | "60 mg/day dose was selected as optimal dose for further studies. Study retrospectively registered on Clinicaltrials.gov on February 27, 2024, NCT06292351."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia (clinicaltrials.gov) - P3 | N=450 | Recruiting | Sponsor: Bigespas LTD

New P3 trial • Alzheimer's Disease • CNS Disorders • Dementia

DMB-I in the Treatment of Alzheimer Type Dementia (clinicaltrials.gov) - P2 | N=133 | Completed | Sponsor: Bigespas LTD | Active, not recruiting ➔ Completed

Trial completion • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023 (BioXcel Therapeutics Press Release) - "To discuss agitation relief in Alzheimer'ss disease and BXCL502 as a potential treatment."

Live event